In the present invention, as a result of detailed research into the expression, over-amplification, mutation and translocation, and the like of FGFR coding genes in a variety of cancer cells, a novel fusion polypeptide obtained by fusion of FGFR3 polypeptide with another polypeptide was identified and isolated in multiple urinary bladder cancer-derived cells and lung cancer cells. By using this fusion polypeptide as a biomarker in cancer therapy with an FGFR inhibitor, it is possible to preemptively prevent the manifestation of side effects in therapy with an FGFR inhibitor and control the therapeutic mode such that the best possible therapeutic results are obtained, and individualized medical treatment is possible.
在本发明中,通过对多种癌细胞中
表皮生长因子受体编码
基因的表达、过度扩增、突变和易位等进行详细研究,在多种膀胱癌衍生细胞和肺癌细胞中发现并分离出了一种新型融合
多肽,该
多肽由
表皮生长因子受体 3
多肽与另一种
多肽融合而成。在使用
表皮生长因子受体
抑制剂进行癌症治疗时,将这种融合
多肽作为
生物标记物,可以预先防止
表皮生长因子受体
抑制剂在治疗过程中产生副作用,并控制治疗模式,从而获得最佳治疗效果,实现个体化治疗。